Artia Global Partners LP Acquires New Shares in Celcuity, Inc. $CELC

Artia Global Partners LP acquired a new stake in Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,900 shares of the company’s stock, valued at approximately $1,287,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CELC. Avoro Capital Advisors LLC bought a new stake in Celcuity in the fourth quarter valued at about $310,302,000. NEA Management Company LLC increased its holdings in Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. State Street Corp increased its holdings in Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after purchasing an additional 914,887 shares during the last quarter. Apis Capital Advisors LLC bought a new stake in Celcuity in the third quarter valued at about $38,334,000. Finally, UBS Group AG increased its holdings in Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Up 0.8%

Shares of Celcuity stock opened at $88.05 on Thursday. Celcuity, Inc. has a 1 year low of $11.27 and a 1 year high of $151.02. The business has a 50-day moving average of $118.29 and a two-hundred day moving average of $111.04. The company has a market capitalization of $4.29 billion, a P/E ratio of -22.58 and a beta of 0.10. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.10. As a group, equities analysts predict that Celcuity, Inc. will post -3.69 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CELC shares. Weiss Ratings upgraded Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Wolfe Research restated an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a report on Thursday, March 12th. Guggenheim restated a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Craig Hallum lowered their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Macquarie Infrastructure set a $160.00 price target on Celcuity in a report on Thursday, May 28th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and an average price target of $152.09.

Insider Activity

In other news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares of the company’s stock, valued at $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock valued at $5,111,950 over the last ninety days. 13.33% of the stock is owned by insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.